During puberty, growth hormone (GH)-deficient children may experience difficulties achieving an appropriate pubertal growth spurt. We review the complex hormonal interactions which occur during puberty. At least two therapeutic strategies have been developed to optimize GH therapy during puberty. In the first strategy, the GH dose administered per kilogram of body weight is increased during puberty, in an attempt to mimic the physiological increase of GH which occurs during puberty. In the second strategy, luteinizing hormone-releasing hormone (LHRH) analogs are administered concomitantly with GH with the aim of delaying epiphyseal fusion. The efficacy of these strategies to increase final height has not previously been clearly demonstrated...
We studied 30 girls (age 6.36 +/- 1.21 years, range 4.6-8.8) affected by idiopathic precocious puber...
Aim: To analyze the height gain in children with precocious puberty who have been treated with GnRH-...
Background/Aims: Growth hormone (GH) treatment regimens do not account for the pubertal increase in ...
Abstract: In the setting of central precocious puberty (CPP), the motivation for hormonal interventi...
Although recombinant techniques have enabled the production of limitless amounts of human growth hor...
Luteinizing Hormone Releasing Hormone analogues (LHRHa) are considered the treatment of choice in ce...
The availability of recombinant human growth hormone (GH) and the optimization of substitutive thera...
In subjects with an isolated GH deficiency the inhibition of puberty by GnRH-analogue administration...
Experiments of nature and clinical observations have provided indications that postponing puberty ma...
To assess whether delaying puberty may improve final height in GH-deficient children with a poor hei...
Background: Girls adopted from developing countries often have early or precocious puberty, requirin...
GnRH analogs (GnRHa) arrest pubertal development and slow growth velocity (GV) and bone maturation, ...
Objective: This study was conducted to study the role of combination therapy of growth hormone and G...
Growth hormone-insulin-like growth factor-I status and response to growth hormone therapy (0.6IU/kg/...
We studied 30 girls (age 6.36 +/- 1.21 years, range 4.6-8.8) affected by idiopathic precocious puber...
We studied 30 girls (age 6.36 +/- 1.21 years, range 4.6-8.8) affected by idiopathic precocious puber...
Aim: To analyze the height gain in children with precocious puberty who have been treated with GnRH-...
Background/Aims: Growth hormone (GH) treatment regimens do not account for the pubertal increase in ...
Abstract: In the setting of central precocious puberty (CPP), the motivation for hormonal interventi...
Although recombinant techniques have enabled the production of limitless amounts of human growth hor...
Luteinizing Hormone Releasing Hormone analogues (LHRHa) are considered the treatment of choice in ce...
The availability of recombinant human growth hormone (GH) and the optimization of substitutive thera...
In subjects with an isolated GH deficiency the inhibition of puberty by GnRH-analogue administration...
Experiments of nature and clinical observations have provided indications that postponing puberty ma...
To assess whether delaying puberty may improve final height in GH-deficient children with a poor hei...
Background: Girls adopted from developing countries often have early or precocious puberty, requirin...
GnRH analogs (GnRHa) arrest pubertal development and slow growth velocity (GV) and bone maturation, ...
Objective: This study was conducted to study the role of combination therapy of growth hormone and G...
Growth hormone-insulin-like growth factor-I status and response to growth hormone therapy (0.6IU/kg/...
We studied 30 girls (age 6.36 +/- 1.21 years, range 4.6-8.8) affected by idiopathic precocious puber...
We studied 30 girls (age 6.36 +/- 1.21 years, range 4.6-8.8) affected by idiopathic precocious puber...
Aim: To analyze the height gain in children with precocious puberty who have been treated with GnRH-...
Background/Aims: Growth hormone (GH) treatment regimens do not account for the pubertal increase in ...